Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellerant Therapeutics has received additional funding of approximately $16.7m from Biomedical Advanced Research and Development Authority (BARDA) to advance CLT-008 development as a treatment for acute radiation syndrome (ARS).
Subscribe to our email newsletter
The additional funding is expected to support Cellerant’s CLT-008 development strategy to expand its current clinical trials, process development and manufacturing activities and to fund additional nonclinical studies required for approval in ARS.
The current funding is a part of an existing contract valued at up to $153.2m previously awarded on 1 September 2010.
As per the revised deal, BARDA will grant up to $80m, in the two year base period of performance and up to an additional $89.9m in three option years, bringing the total value of the contract to $169.9m.
Cellerant president and CEO Ram Mandalam said they continue to make progress and the supplemental funding provides additional resources to advance CLT-008 closer to approval for therapeutic use.